Nadezhda Novikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadezhda Novikova has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Elena Igorevna Ermolenko
Institute of Experimental Medicine, 197376 St. Petersburg, Russia
11 shared publications - Alexander N. Suvorov
Institute of Experimental Medicine, 197376 Saint-Petersburg, Russia
4 shared publications - Nikita S. Gladyshev
Petrovsky National Research Centre of Surgery, Moscow 117418, Russia
4 shared publications - Alena Borisovna Karaseva
Federal State Budgetary Scientific Institution «Institute of Experimental Medicine» (FSBSI «IEM»), Str. Academica Pavlova 12, St. Petersburg 197022, Russia
3 shared publications - Alexandra Olegovna Konradi
Almazov National Medical Research Centre
3 shared publications - Alexey L. Maslyanskiy
Almazov National Medical Research Centre, St. Petersburg, Russia
3 shared publications
Latest Publications
- Open Access
Autoprobiotic Supplements Attenuate Obesity and Improve Gut Microbiota, Carbohydrate, and Lipid Metabolism in Patients with Metabolic Syndrome: A Pilot Trial
Background/Objectives: A pilot study was conducted to evaluate the effectiveness of treatment with autoprobiotic bacteria from indigenous, non-pathogenic Enterococcus faecium and Enterococcus hirae strains in patients with metabolic syndrome (MetS). Methods: Fifty patients with MetS (sex-matched, aged 42–63 years) were randomized to an experimental group (Ap, n = 26) that received autoprobiotics grown in nutritional mix SuproPlus 2640 and a control group (Pl, n = 24) that received SuproPlus 2640 for 20 days. Results: The effects of therapy on anthropometric and biochemical parameters, as well as the gut microbiome, were assessed on days 14 and 28 after the autoprobiotic course. Autoprobiotic treatment reduced the severity of obesity symptoms and led to decreases in serum glucose and glycated hemoglobin (HbAc1) levels and partial normalization of the lipid profile. An intergroup comparison revealed lower concentrations of HbAc1 and triglycerides in blood serum when comparing samples taken from Ap and Pl groups on day 28 after therapy. qPCR showed a reduction in the numbers of Bacteroides fragilis group, Streptococcus spp., and Ruminococcus spp. in the Ap group. The 16S rRNA gene sequencing results provided a longitudinal model for relative abundance analysis of the observed taxa, and comparison between dynamic parameters indicated a more favorable trend in the Ap group, with a decrease in the relative abundance of Oscillospiraceae UCG-003 and an increase in that of “Prevotellamassilia” observed only in this group. Longitudinal microbiota analysis using the coda4microbiome package demonstrated that the most pronounced microbiome shifts occurred in the Ap group, with the genera Senegalimassilia, “Prevotellamassilia”, Streptococcus, Paraprevotella, and Anaerobutyricum contributing substantially. Conclusions: Autoprobiotic Enterococcus spp. may affect the gut microbiome and is potentially effective for treating MetS.
Open AccessAutoprobiotic Supplements Attenuate Obesity and Improve Gut Microbiota, Carbohydrate, and Lipid Metabolism in Patients with Metabolic Syndrome: A Pilot Trial
Background/Objectives: A pilot study was conducted to evaluate the effectiveness of treatment with autoprobiotic bacteria from indigenous, non-pathogenic Enterococcus faecium and Enterococcus hirae strains in patients with metabolic syndrome (MetS). Methods: Fifty patients with MetS (sex-matched, aged 42–63 years) were randomized to an experimental group (Ap, n = 26) that received autoprobiotics grown in nutritional mix SuproPlus 2640 and a control group (Pl, n = 24) that received SuproPlus 2640 for 20 days. Results: The effects of therapy on anthropometric and biochemical parameters, as well as the gut microbiome, were assessed on days 14 and 28 after the autoprobiotic course. Autoprobiotic treatment reduced the severity of obesity symptoms and led to decreases in serum glucose and glycated hemoglobin (HbAc1) levels and partial normalization of the lipid profile. An intergroup comparison revealed lower concentrations of HbAc1 and triglycerides in blood serum when comparing samples taken from Ap and Pl groups on day 28 after therapy. qPCR showed a reduction in the numbers of Bacteroides fragilis group, Streptococcus spp., and Ruminococcus spp. in the Ap group. The 16S rRNA gene sequencing results provided a longitudinal model for relative abundance analysis of the observed taxa, and comparison between dynamic parameters indicated a more favorable trend in the Ap group, with a decrease in the relative abundance of Oscillospiraceae UCG-003 and an increase in that of “Prevotellamassilia” observed only in this group. Longitudinal microbiota analysis using the coda4microbiome package demonstrated that the most pronounced microbiome shifts occurred in the Ap group, with the genera Senegalimassilia, “Prevotellamassilia”, Streptococcus, Paraprevotella, and Anaerobutyricum contributing substantially. Conclusions: Autoprobiotic Enterococcus spp. may affect the gut microbiome and is potentially effective for treating MetS.
- Open Access
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 341-353
Features of the gut microbiome in mice with polygenic disorders of energy metabolism
Objective. To identify features of the gut microbiome using 16S rRNA gene sequencing in inbred KK.Cg-a/a (KK) mice and the KK.Cg-Ay/a (Ay) subline with metabolic syndrome (MetS) caused by different genetic disorders, compared to the C57BL/6J (B6) mouse line lacking manifestations of the pathology. Materials and methods. 3–4 months old male mice of three mouse lines were used: 1) KK mice with polygenic genomic disorders contributing to hyperglycemia, insulin resistance, and hyperinsulinemia; 2) the Ay substrain carrying an additional mutant dominant allele of the Agouti yellow coat color gene, exhibiting more severe MetS manifestations; 3) the B6 mouse line, not prone to obesity and diabetes (control group). All mice were of the same age (2 months) and sex (males) and received a normocaloric diet. Morphometry was performed for each animal, and biochemical parameters of blood serum were analyzed. PCR analysis of mRNA expression of neuropeptides and receptors in the hypothalamus was conducted. Mouse fecal samples were examined using 16S rRNA metagenomic analysis. Results. As previously shown, in male mice with genome-wide disorders on a normocaloric diet, obesity and alterations in carbohydrate and lipid metabolism developed, being more pronounced in the Ay group. Animals of the Ay substrain differed from other mice by greater body and liver weight, higher plasma glucose and leptin concentrations, and increased expression of Neuropeptide Y (NPY), Pro-opiomelanocortin (POMC), and Tas1r3. In all animals with MetS, the microbiome differed from the control group by a lower abundance of the family Muribaculaceae and the genus Akkermansia, and an increased percentage of the phylum Bacteroidota (genera Alistipes, Odoribacter, and Bacteroides). A distinctive feature of the Ay microbiome was an increased percentage of the families Enterobacteriaceae and Oscillospiraceae (Ruminococcaceae). Conclusion. Specific features of the gut microbiome characteristic of inbred animals with varying severities of energy metabolism disorders were identified. The models used can be employed to study the pathogenesis of MetS considering the role of microbiota, as well as to develop methods for predicting disease severity and correcting dysbiotic disturbances arising from energy metabolism disorders.
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 341-353
Open AccessFeatures of the gut microbiome in mice with polygenic disorders of energy metabolism
Objective. To identify features of the gut microbiome using 16S rRNA gene sequencing in inbred KK.Cg-a/a (KK) mice and the KK.Cg-Ay/a (Ay) subline with metabolic syndrome (MetS) caused by different genetic disorders, compared to the C57BL/6J (B6) mouse line lacking manifestations of the pathology. Materials and methods. 3–4 months old male mice of three mouse lines were used: 1) KK mice with polygenic genomic disorders contributing to hyperglycemia, insulin resistance, and hyperinsulinemia; 2) the Ay substrain carrying an additional mutant dominant allele of the Agouti yellow coat color gene, exhibiting more severe MetS manifestations; 3) the B6 mouse line, not prone to obesity and diabetes (control group). All mice were of the same age (2 months) and sex (males) and received a normocaloric diet. Morphometry was performed for each animal, and biochemical parameters of blood serum were analyzed. PCR analysis of mRNA expression of neuropeptides and receptors in the hypothalamus was conducted. Mouse fecal samples were examined using 16S rRNA metagenomic analysis. Results. As previously shown, in male mice with genome-wide disorders on a normocaloric diet, obesity and alterations in carbohydrate and lipid metabolism developed, being more pronounced in the Ay group. Animals of the Ay substrain differed from other mice by greater body and liver weight, higher plasma glucose and leptin concentrations, and increased expression of Neuropeptide Y (NPY), Pro-opiomelanocortin (POMC), and Tas1r3. In all animals with MetS, the microbiome differed from the control group by a lower abundance of the family Muribaculaceae and the genus Akkermansia, and an increased percentage of the phylum Bacteroidota (genera Alistipes, Odoribacter, and Bacteroides). A distinctive feature of the Ay microbiome was an increased percentage of the families Enterobacteriaceae and Oscillospiraceae (Ruminococcaceae). Conclusion. Specific features of the gut microbiome characteristic of inbred animals with varying severities of energy metabolism disorders were identified. The models used can be employed to study the pathogenesis of MetS considering the role of microbiota, as well as to develop methods for predicting disease severity and correcting dysbiotic disturbances arising from energy metabolism disorders.
- Open Access
- 13 May 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 980
Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period
Despite great advances in the treatment of oncological diseases, the development of medical technologies to prevent or reduce complications of therapy, in particular, those associated with surgery and the introduction of antibiotics, remains relevant. The aim of this study is to evaluate the effectiveness of the use of autoprobiotics based on indigenous non-pathogenic strains of Enterococcus faecium and Enterococcus hirae as a personalized functional food product (PFFP) in the complex therapy of colorectal cancer (CRC) in the early postoperative period. A total of 36 patients diagnosed with CRC were enrolled in the study. Study group A comprised 24 CRC patients who received autoprobiotic therapy in the early postoperative period, while the control group C included 12 CRC patients without autoprobiotic therapy. Prior to surgery and between days 14 and 16 post-surgery, comprehensive evaluations were conducted on all patients, encompassing the following: stool and gastroenterological complaints analysis, examination of the gut microbiota (bacteriological study, quantitative polymerase chain reaction, metagenome analysis), and analysis of interleukins in the serum. Results: The use of autoprobiotics led to a decrease in dyspeptic complaints after surgery. It was also associated with the absence of postoperative complications, did not cause any side effects, and led to a decrease in the level of pro-inflammatory cytokines (IL-6 and IL-18) in the blood serum. The use of autoprobiotics led to positive changes in the structure of escherichia and enterococci populations, the elimination of Parvomonas micra and Fusobacterium nucleatum, and a decrease in the quantitative content of Clostridium perfringens and Akkermansia muciniphila. Metagenomic analysis (16S rRNA) revealed an increase in alpha diversity. Conclusion: The introduction of autoprobiotics in the postoperative period is a highly effective and safe approach in the complex treatment of CRC. Future studies will allow the discovery of additional fine mechanisms of autoprobiotic therapy and its impact on the digestive, immune, endocrine, and neural systems.
- 13 May 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 980
Open AccessAutoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period
Despite great advances in the treatment of oncological diseases, the development of medical technologies to prevent or reduce complications of therapy, in particular, those associated with surgery and the introduction of antibiotics, remains relevant. The aim of this study is to evaluate the effectiveness of the use of autoprobiotics based on indigenous non-pathogenic strains of Enterococcus faecium and Enterococcus hirae as a personalized functional food product (PFFP) in the complex therapy of colorectal cancer (CRC) in the early postoperative period. A total of 36 patients diagnosed with CRC were enrolled in the study. Study group A comprised 24 CRC patients who received autoprobiotic therapy in the early postoperative period, while the control group C included 12 CRC patients without autoprobiotic therapy. Prior to surgery and between days 14 and 16 post-surgery, comprehensive evaluations were conducted on all patients, encompassing the following: stool and gastroenterological complaints analysis, examination of the gut microbiota (bacteriological study, quantitative polymerase chain reaction, metagenome analysis), and analysis of interleukins in the serum. Results: The use of autoprobiotics led to a decrease in dyspeptic complaints after surgery. It was also associated with the absence of postoperative complications, did not cause any side effects, and led to a decrease in the level of pro-inflammatory cytokines (IL-6 and IL-18) in the blood serum. The use of autoprobiotics led to positive changes in the structure of escherichia and enterococci populations, the elimination of Parvomonas micra and Fusobacterium nucleatum, and a decrease in the quantitative content of Clostridium perfringens and Akkermansia muciniphila. Metagenomic analysis (16S rRNA) revealed an increase in alpha diversity. Conclusion: The introduction of autoprobiotics in the postoperative period is a highly effective and safe approach in the complex treatment of CRC. Future studies will allow the discovery of additional fine mechanisms of autoprobiotic therapy and its impact on the digestive, immune, endocrine, and neural systems.
- Open Access
- 27 September 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (5) , 442-455
Role of intestinal microbiota in the development of cardiovascular disease: focus on metabolites and markers of increased intestinal permeability and inflammation of the intestinal wall
In recent years, an increasing number of studies have shown a close relationship between the composition and function of the microbiota and human health, including cardiovascular diseases (CVD). Increased intestinal permeability is one of the factors that can influence the state of the microbiota and also lead to the penetration of bacteria and their toxins into the bloodstream, causing systemic inflammation. Chronic inflammation, in turn, is accompanied by increased levels of cytokines, which can cause endothelial damage and lead to endothelial dysfunction. Metabolites of some bacteria can reduce the production of molecules that regulate vascular tone, such as nitric oxide, which can lead to vasoconstriction and hypertension. The review focuses on the connection between calprotectin, zonulin, and trimethylamine oxide with the risk of CVD, and also highlights possible methods for correcting the composition and function of the microbiota for the prevention of CVD.
- 27 September 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (5) , 442-455
Open AccessRole of intestinal microbiota in the development of cardiovascular disease: focus on metabolites and markers of increased intestinal permeability and inflammation of the intestinal wall
In recent years, an increasing number of studies have shown a close relationship between the composition and function of the microbiota and human health, including cardiovascular diseases (CVD). Increased intestinal permeability is one of the factors that can influence the state of the microbiota and also lead to the penetration of bacteria and their toxins into the bloodstream, causing systemic inflammation. Chronic inflammation, in turn, is accompanied by increased levels of cytokines, which can cause endothelial damage and lead to endothelial dysfunction. Metabolites of some bacteria can reduce the production of molecules that regulate vascular tone, such as nitric oxide, which can lead to vasoconstriction and hypertension. The review focuses on the connection between calprotectin, zonulin, and trimethylamine oxide with the risk of CVD, and also highlights possible methods for correcting the composition and function of the microbiota for the prevention of CVD.
- 16 August 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (11)
Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders
Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors. Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years. Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out. Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns. Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.
- 16 August 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (11)
Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders
Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors. Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years. Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out. Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns. Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.
- Open Access
- 16 August 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (11) , 5569
Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders
Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years.Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out.Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns.Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.
- 16 August 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (11) , 5569
Open AccessAssociation of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders
Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years.Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out.Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns.Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.
- Open Access
- 20 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6837
Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome
Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied. We aimed to evaluate the influence of metformin on the intestinal microbiota (IM), metabolism, and functional and morphological characteristics of myocardium in rats with IGT. IGT was modelled in SPF Wistar rats with a high-fat diet and streptozotocin and nicotinamide injection. Rats were divided into three groups: IGT (without treatment), IGT MET (metformin therapy), and CRL (without IGT induction and treatment). IGT group was characterized by: higher body weight, increased serum glucose and total cholesterol levels, atherogenic coefficient, impairment in the functional parameters of the isolated heart during perfusion, and larger myocardium infarction (MI) size in comparison with the CRL group. IM of IGT rats differed from that of CRL: an increase of Bacteroides, Acinetobacter, Akkermansia, Roseburia, and a decrease of Lactobacillus genera representation. Metformin therapy led to the diminishing of metabolic syndrome (MS) symptoms, which correlated with IM restoration, especially with the growth of Akkermansia spp. and decline of Roseburia populations and their influence on other members of IM. The obtained results allow us to consider from a new point of view the expediency of probiotic A. muciniphila use for MS treatment.
- 20 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6837
Open AccessMetformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome
Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied. We aimed to evaluate the influence of metformin on the intestinal microbiota (IM), metabolism, and functional and morphological characteristics of myocardium in rats with IGT. IGT was modelled in SPF Wistar rats with a high-fat diet and streptozotocin and nicotinamide injection. Rats were divided into three groups: IGT (without treatment), IGT MET (metformin therapy), and CRL (without IGT induction and treatment). IGT group was characterized by: higher body weight, increased serum glucose and total cholesterol levels, atherogenic coefficient, impairment in the functional parameters of the isolated heart during perfusion, and larger myocardium infarction (MI) size in comparison with the CRL group. IM of IGT rats differed from that of CRL: an increase of Bacteroides, Acinetobacter, Akkermansia, Roseburia, and a decrease of Lactobacillus genera representation. Metformin therapy led to the diminishing of metabolic syndrome (MS) symptoms, which correlated with IM restoration, especially with the growth of Akkermansia spp. and decline of Roseburia populations and their influence on other members of IM. The obtained results allow us to consider from a new point of view the expediency of probiotic A. muciniphila use for MS treatment.
- Open Access
- 17 June 2022
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 14 (1) , 77-88
The use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus
BACKGROUND: Bacteria in the gastrointestinal tract regulate eating behavior and metabolic processes. A number of probiotic strains have a positive effect on glucose and insulin metabolism. A series of studies have demonstrated the effectiveness of autoprobiotic therapy in the treatment of patients with gastrointestinal diseases. The efficacy and safety of an indigenous strain of Enterococcus faecium in overweight patients with type 2 diabetes has not been studied in the past. AIM: To evaluate the effectiveness of products containing the probiotic strain Enterococcus faecium L3 or the indigenous strain Enterococcus faecium in patients with diabetes mellitus (DM) type 2. MATERIALS AND METHODS: Patients with diabetes mellitus type 2 were randomized into two groups: group of probiotic therapy with an industrial strain of Enterococcus faecium L3 (11 patients); group of autoprobiotic therapy based on an indigenous strain of Enterococcus faecium (9 patients). Therapy was for 14 days. Before and 10-14 days after the end of therapy, anthropometric parameters were assessed; psychometric testing was carried out; biochemical parameters of blood serum were studied. The intestinal microbiota was studied by real-time polymerase chain reaction. RESULTS: Probiotic therapy based on Enterococcus faecium L3 and autoprobiotic therapy based on indigenous Enterococcus faecium had no significant effect on glucose metabolism in patients with type 2 DM. In the Enterococcus faecium L3 group and the group of indigenous Enterococcus faecium there was a significant decrease in gastroenterological complaints on scales of the GSRS questionnaire. Patients in both groups showed a statistically significant decrease in the total bacterial mass, an increase in the quantitative content of Lactobacillus spp., a decrease in the population of Bifidobacterium spp. and Bacteroides thetaiotaomicron. CONCLUSIONS: The probiotic strain Enterococcus faecium L3 and the indigenous Enterococcus faecium do not have a significant effect on the metabolism of glucose and insulin, while they contribute to a similar change in the component composition of the microbiota and a decrease in the severity of gastroenterological complaints.
- 17 June 2022
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 14 (1) , 77-88
Open AccessThe use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus
BACKGROUND: Bacteria in the gastrointestinal tract regulate eating behavior and metabolic processes. A number of probiotic strains have a positive effect on glucose and insulin metabolism. A series of studies have demonstrated the effectiveness of autoprobiotic therapy in the treatment of patients with gastrointestinal diseases. The efficacy and safety of an indigenous strain of Enterococcus faecium in overweight patients with type 2 diabetes has not been studied in the past. AIM: To evaluate the effectiveness of products containing the probiotic strain Enterococcus faecium L3 or the indigenous strain Enterococcus faecium in patients with diabetes mellitus (DM) type 2. MATERIALS AND METHODS: Patients with diabetes mellitus type 2 were randomized into two groups: group of probiotic therapy with an industrial strain of Enterococcus faecium L3 (11 patients); group of autoprobiotic therapy based on an indigenous strain of Enterococcus faecium (9 patients). Therapy was for 14 days. Before and 10-14 days after the end of therapy, anthropometric parameters were assessed; psychometric testing was carried out; biochemical parameters of blood serum were studied. The intestinal microbiota was studied by real-time polymerase chain reaction. RESULTS: Probiotic therapy based on Enterococcus faecium L3 and autoprobiotic therapy based on indigenous Enterococcus faecium had no significant effect on glucose metabolism in patients with type 2 DM. In the Enterococcus faecium L3 group and the group of indigenous Enterococcus faecium there was a significant decrease in gastroenterological complaints on scales of the GSRS questionnaire. Patients in both groups showed a statistically significant decrease in the total bacterial mass, an increase in the quantitative content of Lactobacillus spp., a decrease in the population of Bifidobacterium spp. and Bacteroides thetaiotaomicron. CONCLUSIONS: The probiotic strain Enterococcus faecium L3 and the indigenous Enterococcus faecium do not have a significant effect on the metabolism of glucose and insulin, while they contribute to a similar change in the component composition of the microbiota and a decrease in the severity of gastroenterological complaints.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 25 (6)
Intestinal microbiota, gastroenterological complaints and quality of life in overweight, obese and type 2 diabetes patients
Количественная и качественная характеристика кишечной микробиоты определяет наличие и выраженность метаболических нарушений у пациентов с избыточной массой тела, ожирением и сахарным диабетом (СД) 2-го типа. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить количественные и качественные характеристики кишечной микробиоты, гастроэнтерологические жалобы и качество жизни пациентов с избыточной массой тела, ожирением и СД 2-го типа. МАТЕРИАЛ И МЕТОДЫ В исследование включен 51 пациент с избыточной массой тела, ожирением. Пациентам измеряли массу тела, рост, окружность талии; кишечную микробиоту изучали методом полимеразной цепной реакции в режиме реального времени; определяли содержание в сыворотке крови аланинаминотрансферазы, аспартатаминотрансферазы, щелочной фосфатазы, гамма-глутамилтранспептидазы, билирубина по фракциям, альбумина, глюкозы, инсулина, лактатдегидрогеназы, триглицеридов, общего холестерина, липопротеидов низкой плотности, липопротеидов высокой плотности, С-реактивного белка. Пациенты заполняли опросники GSRS, SF-36. Проведено сравнение характеристики кишечной микробиоты пациентов с избыточной массой тела и ожирением, пациентов с СД 2-го типа и без СД 2-го типа. Осуществлен поиск клинических, физикальных, лабораторных параметров, коррелирующих с концентрацией кишечных бактерий. РЕЗУЛЬТАТЫ В исследование включены 19 (37%) мужчин и 32 (63%) женщины. Медиана возраста составила 54 [44; 63] года, медиана индекса массы тела — 30,99 [28,62; 34,44] кг/м2. Абдоминальное ожирение выявлено у 46 (90,2%) пациентов, СД 2-го типа — у 28 (54,9%) пациентов. Различия между показателями у пациентов с СД 2-го типа и без него: общая бактериальная масса — 12,00 [10,00; 12,78] по сравнению с 10,78 [9,78; 11,48] (p=0,004); Lactobacillus spp. — 0,00 [0,00; 5,00] по сравнению с 5,00 [5,00; 5,70] (pEscherichia coli — 8,30 [6,90; 9,00] по сравнению с 6,60 [6,30; 7,78] (pBacteroides spp. — 11,92 [10,70; 13,00] по сравнению с 10,78 [9,78; 11,30] (pBacteroides thetaiotaomicron — 7,30 [0,00; 9,00] по сравнению с 0,00 [0,00; 6,95] (p=0,010); Akkermansia muciniphila — 0,00 [0,00; 0,00] по сравнению с 6,30 [0,00; 8,48] log10 КОЕ/г (p=0,05). На фоне нарастания окружности талии уменьшалась концентрация в стуле Lactobacillus spp., нарастали концентрации E. coli, Bacteroides spp. и Staphylococcus aureus. Нарастание концентрации A. muciniphila и Lactobacillus spp. сопровождалось уменьшением биохимических маркеров метаболических нарушений. ЗАКЛЮЧЕНИЕ Результаты исследования показали, что концентрация ряда кишечных бактерий связана с наличием сахарного диабета 2-го типа и другими метаболическими расстройствами.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 25 (6)
Intestinal microbiota, gastroenterological complaints and quality of life in overweight, obese and type 2 diabetes patients
Количественная и качественная характеристика кишечной микробиоты определяет наличие и выраженность метаболических нарушений у пациентов с избыточной массой тела, ожирением и сахарным диабетом (СД) 2-го типа. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить количественные и качественные характеристики кишечной микробиоты, гастроэнтерологические жалобы и качество жизни пациентов с избыточной массой тела, ожирением и СД 2-го типа. МАТЕРИАЛ И МЕТОДЫ В исследование включен 51 пациент с избыточной массой тела, ожирением. Пациентам измеряли массу тела, рост, окружность талии; кишечную микробиоту изучали методом полимеразной цепной реакции в режиме реального времени; определяли содержание в сыворотке крови аланинаминотрансферазы, аспартатаминотрансферазы, щелочной фосфатазы, гамма-глутамилтранспептидазы, билирубина по фракциям, альбумина, глюкозы, инсулина, лактатдегидрогеназы, триглицеридов, общего холестерина, липопротеидов низкой плотности, липопротеидов высокой плотности, С-реактивного белка. Пациенты заполняли опросники GSRS, SF-36. Проведено сравнение характеристики кишечной микробиоты пациентов с избыточной массой тела и ожирением, пациентов с СД 2-го типа и без СД 2-го типа. Осуществлен поиск клинических, физикальных, лабораторных параметров, коррелирующих с концентрацией кишечных бактерий. РЕЗУЛЬТАТЫ В исследование включены 19 (37%) мужчин и 32 (63%) женщины. Медиана возраста составила 54 [44; 63] года, медиана индекса массы тела — 30,99 [28,62; 34,44] кг/м2. Абдоминальное ожирение выявлено у 46 (90,2%) пациентов, СД 2-го типа — у 28 (54,9%) пациентов. Различия между показателями у пациентов с СД 2-го типа и без него: общая бактериальная масса — 12,00 [10,00; 12,78] по сравнению с 10,78 [9,78; 11,48] (p=0,004); Lactobacillus spp. — 0,00 [0,00; 5,00] по сравнению с 5,00 [5,00; 5,70] (pEscherichia coli — 8,30 [6,90; 9,00] по сравнению с 6,60 [6,30; 7,78] (pBacteroides spp. — 11,92 [10,70; 13,00] по сравнению с 10,78 [9,78; 11,30] (pBacteroides thetaiotaomicron — 7,30 [0,00; 9,00] по сравнению с 0,00 [0,00; 6,95] (p=0,010); Akkermansia muciniphila — 0,00 [0,00; 0,00] по сравнению с 6,30 [0,00; 8,48] log10 КОЕ/г (p=0,05). На фоне нарастания окружности талии уменьшалась концентрация в стуле Lactobacillus spp., нарастали концентрации E. coli, Bacteroides spp. и Staphylococcus aureus. Нарастание концентрации A. muciniphila и Lactobacillus spp. сопровождалось уменьшением биохимических маркеров метаболических нарушений. ЗАКЛЮЧЕНИЕ Результаты исследования показали, что концентрация ряда кишечных бактерий связана с наличием сахарного диабета 2-го типа и другими метаболическими расстройствами.
- Open Access
- 23 December 2021
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 10,p. 91-99
Gender assessment of the gut microbiome in obese patients
The aim. To assess the relationship between body mass index (BMI) and gut bacteria in men and women with obesity.Materials and methods. The study included 56 overweight patients, divided into 2 groups. The first group consisted of 27 women (the average age was 62 ± 2.2 years), the second group — 29 men (the average age was 55 ± 9 years). The Quetelet index (kg / m2) was calculated for all patients. To study the gut microbiome, the method of polymerase chain reaction in real time (RT-PCR) and metagenomic sequencing were used. DNA from feces was isolated using the Express-DNA-Bio DNA isolation kit (AlkorBio, Russia). To carry out RT-PCR, a set of reagents “Colonoflor-16” (“Alfalab”, Russia) was used. For microbiome sequencing, DNA libraries were prepared using the Illumina Nextera Sample Preparation Kit with DNA primers corresponding to the V3 — V4 regions of the 16S rRNA gene. The study of fecal samples was carried out using 16S rRNA gene sequencing on the Illumina platform (MiSeq sequencer).Results. It was revealed that a higher total number of bacteria, an increased content of Bacteroides fragilis group and Faeca-libacterium prausnitzii, is statistically significantly more common in women than in men. Strong negative correlations were found between BMI and total bacterial mass, between BMI and the number of Bacteroides fragilis group among women with grade I obesity. In overweight men, a correlation was found between BMI and the Bacteroides fragilis group / Faecalibacterium prausnitzii ratio.Conclusions. The total number of bacteria, the content of Bacteroides fragilis group and Faecalibacterium prausnitzii in the gut of patients have statistically significant associations with BMI, and probably can affect the formation of metabolic disorders to a greater extent in women than in men. To clarify the identified trends and patterns in this pilot study, further study of the microbiome with a large number of patients and additional analyzes of the metagenome (16S rRNA) and metabolome, a transcriptome, allowing to control the expression of key metabolic enzymes, largely associated with the compositional features of the gut microbiocenosis, is required.
- 23 December 2021
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 10,p. 91-99
Open AccessGender assessment of the gut microbiome in obese patients
The aim. To assess the relationship between body mass index (BMI) and gut bacteria in men and women with obesity.Materials and methods. The study included 56 overweight patients, divided into 2 groups. The first group consisted of 27 women (the average age was 62 ± 2.2 years), the second group — 29 men (the average age was 55 ± 9 years). The Quetelet index (kg / m2) was calculated for all patients. To study the gut microbiome, the method of polymerase chain reaction in real time (RT-PCR) and metagenomic sequencing were used. DNA from feces was isolated using the Express-DNA-Bio DNA isolation kit (AlkorBio, Russia). To carry out RT-PCR, a set of reagents “Colonoflor-16” (“Alfalab”, Russia) was used. For microbiome sequencing, DNA libraries were prepared using the Illumina Nextera Sample Preparation Kit with DNA primers corresponding to the V3 — V4 regions of the 16S rRNA gene. The study of fecal samples was carried out using 16S rRNA gene sequencing on the Illumina platform (MiSeq sequencer).Results. It was revealed that a higher total number of bacteria, an increased content of Bacteroides fragilis group and Faeca-libacterium prausnitzii, is statistically significantly more common in women than in men. Strong negative correlations were found between BMI and total bacterial mass, between BMI and the number of Bacteroides fragilis group among women with grade I obesity. In overweight men, a correlation was found between BMI and the Bacteroides fragilis group / Faecalibacterium prausnitzii ratio.Conclusions. The total number of bacteria, the content of Bacteroides fragilis group and Faecalibacterium prausnitzii in the gut of patients have statistically significant associations with BMI, and probably can affect the formation of metabolic disorders to a greater extent in women than in men. To clarify the identified trends and patterns in this pilot study, further study of the microbiome with a large number of patients and additional analyzes of the metagenome (16S rRNA) and metabolome, a transcriptome, allowing to control the expression of key metabolic enzymes, largely associated with the compositional features of the gut microbiocenosis, is required.